Industry News

GlycoMimetics, Inc. today announced the publication of results from a preclinical study that showed its drug candidate GMI-1271 reduced the cellular interactions that often lead to a buildup in inflammatory response and unstable atherosclerotic plaque formation after a heart attack. The study, entitled“ E-Selectin..."/>
GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack
StemCells, Inc. and Microbot Medical Ltd., a private company organized under the laws of the State of Israel, today announced that they have entered into a definitive merger agreement, with plans to pursue the development of robotics based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions.. “This transaction concludes an extensive search for strategic alternatives..."/>
StemCells, Inc. and Microbot Medical Ltd. Announce Strategic Merger
Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced the pricing of an underwritten public offering of 1,986,666 shares of its common stock at a price of $7.50 per share.. All shares in the offering are being sold by Recro, with expected gross proceeds to Recro of..."/>
Recro Pharma Announces Pricing of Public Offering of Common Stock
Zynex, an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neuro diagnostics, cardiac and blood volume monitoring, announced today July 2016 electrotherapy orders. Zynex received 1,912 orders during the month of July, 104% more than the 937 orders received in July of last year and 8% less than June orders. Thomas Sandgaard, CEO..."/>
Zynex Announces July Orders
Intuitive Surgical, Inc. today announced the results of a first-of-its-kind, multi-institutional robotic-assisted ventral hernia study. The study titled,“ Robotic- Assisted Ventral Hernia Repair: A Multi Center Evaluation of Clinical Outcomes,” was recently published in Surgical Endoscopy. This study provides real-world evidence for patients undergoing robotic-assisted ventral hernia procedures performed by da Vinci surgeons during..."/>
New Study Shows Robotic-Assisted Surgery Benefits For Ventral Hernia Patients
IsoRay, Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will present at the Rodman& Renshaw 18th Annual Global Investment Conference taking place on September 11-13, 2016 at the Lotte New York Palace Hotel in New York City. Tom LaVoy, CEO, Brien Ragle, CFO, and Bill Cavanagh, COO,..."/>
IsoRay, Inc. to Present at Rodman & Renshaw 18th Annual Global Investment Conference
MGT Capital Investments, Inc. today provided an update on its business and pending acquisitions, as well as its unaudited financial results for the three-month period ended June 30, 2016.. "In the second quarter the Company made significant progress implementing a multi-pronged strategy that has transformed MGT Capital Investments into the innovative cybersecurity company that we envisioned. With the broad set of differing..."/>
MGT Provides Quarterly Corporate Update
Chiasma, Inc., a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it is further reducing its workforce by approximately 44%, primarily in the company’ s research and general and administrative functions, to lower its operating expenses and extend its cash runway. This action follows Chiasma’ s announcement of a corporate restructuring plan in June 2016, which included an..."/>
Chiasma Announces Workforce Reduction
Remedent, Inc., an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the first quarter ended June 30, 2016.. Our 10- Q report is available since Monday August 15, 2016; 4:00 pm EST. Net sales for the three months ended June 30, 2016 are $615,949 and our net income for the quarter ended June 30, 2016 is $101,415 or 16,46% of our net sales over the quarter ended June..."/>
Remedent Confirms the Filing of Its 10-Q Report for the First Quarter Ending June 30, 2016
It's no wonder they are so keen to sell! [Daily Mail, London]
Entertainment One was spurred further forward as anticipation mounted that it may receive another takeover bid. Speculation that ITV would buy the business behind children's television favourite Peppa Pig first began back in April. Last week eOne rejected a pounds sterling 1 bn offer from the broadcaster."/>
Daily Mail, London, market report column [Daily Mail, London]
Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the second quarter of 2016 on Thursday, August 18, 2016. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time to discuss the results and provide a business..."/>
Auris Medical to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on Thursday, August 18, 2016
Forget Brexit, get spending [Daily Mail, London]
Anthera Pharmaceuticals, Inc. today announced that the Data and Safety Monitoring Board completed its first pre-planned safety review of the Phase 3 SOLUTION clinical study of Sollpura™ in cystic fibrosis patients with exocrine pancreatic insufficiency. The DSMB had“ no concerns regarding safety of the data to date, and voted that the study continue without modification to the protocol or charter.”. This follows six positive reviews by a separate..."/>
Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura™
Piramal Enterprises Limited announced today that its wholly owned subsidiary in the US has entered into an agreement to acquire 100% stake in Ash Stevens Inc., a US based Contract Development and Manufacturing Organization, in an all cash deal for a consideration of USD 42.95 million plus an earn-out consideration capped at $10 million. This potential transaction is expected to be completed by the end of August. Located in Riverview, Michigan, Ash Stevens has over..."/>
Piramal Enterprises Enters into an Agreement to Acquire Ash Stevens Inc., a US based CDMO for High Potency APIs (HPAPIs)
Zosano Pharma Corporation, a CNS company focused on providing rapid symptom relief to patients using the Company’ s proprietary intracutaneous delivery system, today announced that it has entered into a securities purchase agreement to sell shares of its common stock and warrants to purchase shares of its common stock at a price of $1.57 per unit in a private placement. This financing will generate aggregate gross proceeds at closing of..."/>
Zosano Pharma Announces Pricing of Private Placement of Common Stock and Warrants
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that it has completed a private placement of its common stock and common stock purchase warrants that will result resulting in gross proceeds to the Company of approximately $2.8 million. The financing was led by the Company’ s existing investors, including affiliates of..."/>
Arno Completes $2.8 Million Private Placement
First Choice Healthcare Solutions, Inc., one of the nation's only non-physician-owned, publicly traded healthcare services companies focused on the delivery of total musculoskeletal solutions with an emphasis on Orthopaedics, including spine care and treatment, today announced its second quarter results for the three and six months ended June 30, 2016.. Chris Romandetti, Chairman, President and CEO of First Choice, stated, "During the second quarter,..."/>
First Choice Healthcare Solutions Reports Continued Profitability and Revenue Growth in Second Quarter 2016
ULURU Inc. today announced its financial results for the second quarter ended June 30, 2016 and provided a review of its operating activities. Commenting on the Company's activities, Helmut Kerschbaumer, Interim President and CEO of ULURU Inc., stated, "We are pleased to report that our ongoing efforts to develop and expand our international distribution footprint are being rewarded. In June 2016, we entered into a cooperation agreement..."/>
ULURU Inc. Reports Financial Results For Second Quarter 2016
Bio-AMD, Inc. and Bio-AMD UK Holdings Ltd., our majority owned medical devices subsidiary here provides a second quarter update. Following withdrawal of a development partner for our Point of Care "prothrombin time/international normalized ratio monitoring system development project earlier this year the Company has actively sought a new, suitable partner to continue the development of its COAG technology. COAG is aimed at patients..."/>
Bio-AMD, Inc. Second Quarter Update
WellCare Health Plans, Inc. today announced that the National Committee for Quality Assurance has awarded its Medicare Advantage health plan in South Carolina a status of Accredited. NCQA accreditation evaluates the quality of health care that health plans provide to their members. It is a nationally recognized evaluation that consumers can use to assess health plans."/>
WellCare Receives NCQA Quality Accreditation for Its Medicare Advantage Health Plan in South Carolina
Nutra Pharma Corporation, a biotechnology company marketing Nyloxin ® and Pet Pain-Away™ in the over-the-counter pain management market, and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus, Adrenomyeloneuropathy and Pain, announced today the appointment of Dan Oran as their newest member of their Board of Directors. They are also announcing the appointment of Dale Vanderputten, PhD as their Chief..."/>
Nutra Pharma Announces Additions to the Board of Directors and Management Team

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary640 Articles
Information Technology613 Articles
Financials488 Articles
Industrials386 Articles
Health Care365 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at